PAVmed And ENDRA Life Sciences On The List Of Winners And Losers Of Wednesday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are PAVmed, NGM Biopharmaceuticals, and PAVmed.

Rank Financial Asset Price Change Updated (EST)
1 PAVmed (PAVMW) 0.03 105.67% 2024-01-03 07:11:05
2 NGM Biopharmaceuticals (NGM) 1.25 45.52% 2024-01-02 22:23:06
3 PAVmed (PAVMZ) 0.15 40.18% 2024-01-03 07:12:06
4 PolyPid Ltd. (PYPD) 6.89 26.47% 2024-01-03 15:49:06
5 Ontrak (OTRKP) 0.59 15.69% 2024-01-03 05:10:06
6 Ocugen (OCGN) 0.66 14.37% 2024-01-03 01:13:05
7 Pulmatrix (PULM) 2.20 13.89% 2024-01-03 15:13:05
8 NeuroBo Pharmaceuticals (NRBO) 4.11 11.44% 2024-01-02 23:13:05
9 National Energy Services Reunited Corp. (NESR) 6.60 8.2% 2024-01-02 21:12:05
10 InVivo Therapeutics Holdings Corp. (NVIV) 0.79 8.16% 2024-01-02 23:46:06

The three biggest losers today are ENDRA Life Sciences, Nemaura Medical, and Passage Bio.

Rank Financial Asset Price Change Updated (EST)
1 ENDRA Life Sciences (NDRA) 1.59 -25% 2024-01-02 21:09:06
2 Nemaura Medical (NMRD) 0.19 -16.36% 2024-01-02 23:06:05
3 Passage Bio (PASG) 0.90 -10.78% 2024-01-03 07:08:06
4 Xerox Corporation (XRX) 16.29 -9.65% 2024-01-03 13:00:39
5 Nikola (NKLA) 0.76 -8.2% 2024-01-03 12:17:05
6 AMC (AMC) 5.64 -7.77% 2024-01-03 12:18:35
7 Enphase Energy (ENPH) 121.51 -7.41% 2024-01-03 12:12:06
8 3D Systems (DDD) 5.70 -7.32% 2024-01-03 12:54:23
9 3D Systems (DDD) 5.70 -7.32% 2024-01-03 12:54:23
10 Plug Power (PLUG) 4.26 -7.3% 2024-01-03 12:14:26

Winners today

1. PAVmed (PAVMW) – 105.67%

NASDAQ ended the session with PAVmed rising 105.67% to $0.03 on Wednesday while NASDAQ fell 1.18% to $14,592.21.

Yearly Top and Bottom Value

PAVmed’s stock is valued at $0.03 at 16:32 EST, way below its 52-week high of $4.74 and way above its 52-week low of $0.02.

Moving Average

PAVmed’s worth is way below its 50-day moving average of $0.21 and way below its 200-day moving average of $1.66.

More news about PAVmed.

2. NGM Biopharmaceuticals (NGM) – 45.52%

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NASDAQ ended the session with NGM Biopharmaceuticals jumping 45.52% to $1.25 on Wednesday, following the last session’s upward trend. NASDAQ fell 1.18% to $14,592.21, after three consecutive sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, NGM Biopharmaceuticals has a trailing twelve months EPS of $-1.83.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -66.33%.

Volume

Today’s last reported volume for NGM Biopharmaceuticals is 23535600 which is 5129.18% above its average volume of 450081.

More news about NGM Biopharmaceuticals.

3. PAVmed (PAVMZ) – 40.18%

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

NASDAQ ended the session with PAVmed jumping 40.18% to $0.15 on Wednesday, after five sequential sessions in a row of losses. NASDAQ dropped 1.18% to $14,592.21, after three successive sessions in a row of losses, on what was an all-around negative trend trading session today.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1358.06%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 940.8%, now sitting on 1.51M for the twelve trailing months.

More news about PAVmed.

4. PolyPid Ltd. (PYPD) – 26.47%

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

NASDAQ ended the session with PolyPid Ltd. rising 26.47% to $6.89 on Wednesday while NASDAQ dropped 1.18% to $14,592.21.

Earnings Per Share

As for profitability, PolyPid Ltd. has a trailing twelve months EPS of $-23.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -320.14%.

Yearly Top and Bottom Value

PolyPid Ltd.’s stock is valued at $6.89 at 16:32 EST, way below its 52-week high of $38.70 and way higher than its 52-week low of $3.57.

Earnings Before Interest, Taxes, Depreciation, and Amortization

PolyPid Ltd.’s EBITDA is -1.29.

More news about PolyPid Ltd..

5. Ontrak (OTRKP) – 15.69%

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with Ontrak jumping 15.69% to $0.59 on Wednesday while NASDAQ fell 1.18% to $14,592.21.

Earnings Per Share

As for profitability, Ontrak has a trailing twelve months EPS of $-2.843.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -714.32%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30.7%, now sitting on 11.71M for the twelve trailing months.

More news about Ontrak.

6. Ocugen (OCGN) – 14.37%

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

NASDAQ ended the session with Ocugen rising 14.37% to $0.66 on Wednesday while NASDAQ fell 1.18% to $14,592.21.

Earnings Per Share

As for profitability, Ocugen has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -98.28%.

More news about Ocugen.

7. Pulmatrix (PULM) – 13.89%

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

NASDAQ ended the session with Pulmatrix rising 13.89% to $2.20 on Wednesday, following the last session’s upward trend. NASDAQ slid 1.18% to $14,592.21, after three successive sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, Pulmatrix has a trailing twelve months EPS of $-4.44.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.18%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.4%, now sitting on 6.8M for the twelve trailing months.

More news about Pulmatrix.

8. NeuroBo Pharmaceuticals (NRBO) – 11.44%

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with NeuroBo Pharmaceuticals rising 11.44% to $4.11 on Wednesday while NASDAQ dropped 1.18% to $14,592.21.

Earnings Per Share

As for profitability, NeuroBo Pharmaceuticals has a trailing twelve months EPS of $-43.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -86.09%.

Moving Average

NeuroBo Pharmaceuticals’s worth is way higher than its 50-day moving average of $3.57 and under its 200-day moving average of $4.18.

Yearly Top and Bottom Value

NeuroBo Pharmaceuticals’s stock is valued at $4.11 at 16:32 EST, way under its 52-week high of $7.60 and way higher than its 52-week low of $2.89.

More news about NeuroBo Pharmaceuticals.

9. National Energy Services Reunited Corp. (NESR) – 8.2%

National Energy Services Reunited Corp. provides oilfield services to oil and gas companies in the Middle East, North Africa, and the Asia Pacific regions. It operates through two segments, Production Services; and Drilling and Evaluation Services. The Production Services segment offers hydraulic fracturing services; coiled tubing services, including nitrogen lifting, fishing, milling, clean-out, scale removal, and other well applications; stimulation and pumping services; primary and remedial cementing services; nitrogen services; filtration services, as well as frac tanks and pumping units; and pipeline services, such as water filling and hydro testing, nitrogen purging, and de-gassing and pressure testing, as well as cutting/welding and cooling down piping/vessels systems. It also provides production assurance chemicals; laboratory services; artificial lift services; and surface and subsurface safety systems, high-pressure packer systems, flow controls, service tools, expandable liner technology, vacuum insulated tubing technology, and engineering capabilities with manufacturing capacity and testing facilities, as well as sources, treats, and disposes water for oil and gas, municipal, and industrial use. The Drilling and Evaluation Services segment offers drilling and workover rigs; rig services; fishing and remedial solutions; directional and turbines drilling services; drilling fluid systems and related technologies; wireline logging services; slickline services for removal of scale, wax and sand build-up, setting plugs, changing out gas lift valves, and fishing and other well applications; and well testing services to measure solids, gas, and oil and water produced from a well, as well as rents drilling tools. It also provides oilfield solutions for thru-tubing intervention; tubular running services; and a range of wellhead products, flow control equipment, and frac equipment. The company was incorporated in 2017 and is headquartered in Houston, Texas.

NASDAQ ended the session with National Energy Services Reunited Corp. jumping 8.2% to $6.60 on Wednesday while NASDAQ fell 1.18% to $14,592.21.

Earnings Per Share

As for profitability, National Energy Services Reunited Corp. has a trailing twelve months EPS of $-0.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.49%.

Sales Growth

National Energy Services Reunited Corp.’s sales growth for the current quarter is 2.7%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 909.52M for the twelve trailing months.

Yearly Top and Bottom Value

National Energy Services Reunited Corp.’s stock is valued at $6.60 at 16:32 EST, way below its 52-week high of $7.73 and way above its 52-week low of $2.44.

More news about National Energy Services Reunited Corp..

10. InVivo Therapeutics Holdings Corp. (NVIV) – 8.16%

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with InVivo Therapeutics Holdings Corp. rising 8.16% to $0.79 on Wednesday, following the last session’s upward trend. NASDAQ dropped 1.18% to $14,592.21, after three consecutive sessions in a row of losses, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, InVivo Therapeutics Holdings Corp. has a trailing twelve months EPS of $-3.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -98.11%.

Volume

Today’s last reported volume for InVivo Therapeutics Holdings Corp. is 46732 which is 88.05% above its average volume of 24850.

Yearly Top and Bottom Value

InVivo Therapeutics Holdings Corp.’s stock is valued at $0.79 at 16:32 EST, way under its 52-week high of $2.80 and way above its 52-week low of $0.60.

Earnings Before Interest, Taxes, Depreciation, and Amortization

InVivo Therapeutics Holdings Corp.’s EBITDA is 2.35.

More news about InVivo Therapeutics Holdings Corp..

Losers Today

1. ENDRA Life Sciences (NDRA) – -25%

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NASDAQ ended the session with ENDRA Life Sciences sliding 25% to $1.59 on Wednesday, following the last session’s downward trend. NASDAQ slid 1.18% to $14,592.21, after three consecutive sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, ENDRA Life Sciences has a trailing twelve months EPS of $-2.56.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -154.42%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 62.5% and 60.2%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ENDRA Life Sciences’s EBITDA is -1.29.

More news about ENDRA Life Sciences.

2. Nemaura Medical (NMRD) – -16.36%

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

NASDAQ ended the session with Nemaura Medical sliding 16.36% to $0.19 on Wednesday while NASDAQ slid 1.18% to $14,592.21.

Earnings Per Share

As for profitability, Nemaura Medical has a trailing twelve months EPS of $-0.39.

More news about Nemaura Medical.

3. Passage Bio (PASG) – -10.78%

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

NASDAQ ended the session with Passage Bio sliding 10.78% to $0.90 on Wednesday, after two sequential sessions in a row of losses. NASDAQ fell 1.18% to $14,592.21, after three successive sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, Passage Bio has a trailing twelve months EPS of $-2.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -64.09%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Passage Bio’s EBITDA is 3.97.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 18.4% and 36.5%, respectively.

Moving Average

Passage Bio’s value is way higher than its 50-day moving average of $0.70 and higher than its 200-day moving average of $0.84.

More news about Passage Bio.

4. Xerox Corporation (XRX) – -9.65%

Xerox Holdings Corporation, a workplace technology company, designs, develops, and sells document management systems and solutions in the Americas, Europe, the Middle East, Africa, India, and internationally. It offers workplace solutions, including desktop monochrome, and color and multifunction printers; digital printing presses and light production devices, and solutions; and digital services that leverage workflow automation, personalization and communication software, content management solutions, and digitization services. The company also provides graphic communications and production solutions; and IT services, end user computing devices, network infrastructure, communications technology, and a range of managed IT solutions, such as technology product support, professional engineering, and commercial robotic process automation; and provides finance for the sale of Xerox, non-Xerox office, and IT services equipment. In addition, it provides FreeFlow a portfolio of software solutions for the automation and integration to the processing of print job comprises file preparation, final production, and electronic publishing. Further, the company sells paper products and wide-format systems, licensing, as well as standalone software such as CareAR, DocuShare, and XMPie. The company sells its products and services directly to its customers through its direct sales force, as well as through independent agents, dealers, value-added resellers, systems integrators, and e-commerce marketplaces. Xerox Holdings Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.

NYSE ended the session with Xerox Corporation dropping 9.65% to $16.29 on Wednesday, after three sequential sessions in a row of losses. NYSE slid 0.77% to $16,712.39, after three sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Xerox Corporation has a trailing twelve months EPS of $1.06.

PE Ratio

Xerox Corporation has a trailing twelve months price to earnings ratio of 15.37. Meaning, the purchaser of the share is investing $15.37 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.6%.

More news about Xerox Corporation.

5. Nikola (NKLA) – -8.2%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola sliding 8.2% to $0.76 on Wednesday while NASDAQ slid 1.18% to $14,592.21.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -159.83%.

Yearly Top and Bottom Value

Nikola’s stock is valued at $0.76 at 16:32 EST, way under its 52-week high of $3.71 and way above its 52-week low of $0.52.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Nikola’s EBITDA is 30.5.

Volatility

Nikola’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.98%, a negative 0.95%, and a positive 4.78%.

Nikola’s highest amplitude of average volatility was 0.98% (last week), 6.39% (last month), and 4.78% (last quarter).

Moving Average

Nikola’s worth is way under its 50-day moving average of $0.98 and way below its 200-day moving average of $1.26.

More news about Nikola.

6. AMC (AMC) – -7.77%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. AMC Entertainment Holdings, Inc. was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC dropping 7.77% to $5.64 on Wednesday while NYSE fell 0.77% to $16,712.39.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-3.

Volatility

AMC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.33%, a negative 0.66%, and a positive 4.05%.

AMC’s highest amplitude of average volatility was 1.14% (last week), 2.75% (last month), and 4.05% (last quarter).

Yearly Top and Bottom Value

AMC’s stock is valued at $5.64 at 16:32 EST, below its 52-week low of $5.93.

Moving Average

AMC’s worth is way under its 50-day moving average of $8.07 and way under its 200-day moving average of $30.84.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 75.1% and 57.9%, respectively.

More news about AMC.

7. Enphase Energy (ENPH) – -7.41%

Enphase Energy, Inc., together with its subsidiaries, designs, develops, manufactures, and sells home energy solutions for the solar photovoltaic industry in the United States and internationally. The company offers semiconductor-based microinverter, which converts energy at the individual solar module level, and combines with its proprietary networking and software technologies to provide energy monitoring and control services. It also provides microinverter units and related accessories, an IQ gateway; IQ batteries; the cloud-based Enlighten monitoring service; storage solutions; and electric vehicle charging solutions; and design, proposal, permitting, and lead generation services. The company sells its solutions to solar distributors; and directly to large installers, original equipment manufacturers, strategic partners, and homeowners, as well as through its legacy product upgrade program or online store. Enphase Energy, Inc. was incorporated in 2006 and is headquartered in Fremont, California.

NASDAQ ended the session with Enphase Energy falling 7.41% to $121.51 on Wednesday, after four successive sessions in a row of losses. NASDAQ fell 1.18% to $14,592.21, after three consecutive sessions in a row of losses, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Enphase Energy has a trailing twelve months EPS of $3.99.

PE Ratio

Enphase Energy has a trailing twelve months price to earnings ratio of 30.45. Meaning, the purchaser of the share is investing $30.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 70.38%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Enphase Energy’s EBITDA is 99.9.

Volume

Today’s last reported volume for Enphase Energy is 3202860 which is 42.76% below its average volume of 5596120.

Revenue Growth

Year-on-year quarterly revenue growth declined by 13.2%, now sitting on 2.71B for the twelve trailing months.

Volatility

Enphase Energy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.32%, a positive 1.19%, and a positive 3.39%.

Enphase Energy’s highest amplitude of average volatility was 1.32% (last week), 3.34% (last month), and 3.39% (last quarter).

More news about Enphase Energy.

8. 3D Systems (DDD) – -7.32%

3D Systems Corporation provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers 3D printers technologies, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, polymer extrusion, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and biocompatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable goods, government, defense, technology, jewelry, electronic, education, consumer goods, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems dropping 7.32% to $5.70 on Wednesday, after four consecutive sessions in a row of losses. NYSE fell 0.77% to $16,712.39, after three sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.33%.

Yearly Top and Bottom Value

3D Systems’s stock is valued at $5.70 at 16:32 EST, way below its 52-week high of $12.67 and way above its 52-week low of $3.50.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 83.3% and 66.7%, respectively.

More news about 3D Systems.

9. 3D Systems (DDD) – -7.32%

3D Systems Corporation provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers 3D printers technologies, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, polymer extrusion, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and biocompatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable goods, government, defense, technology, jewelry, electronic, education, consumer goods, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems sliding 7.32% to $5.70 on Wednesday while NYSE slid 0.77% to $16,712.39.

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-0.73.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.33%.

Volume

Today’s last reported volume for 3D Systems is 966999 which is 55.18% below its average volume of 2157800.

Volatility

3D Systems’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.44%, a positive 0.52%, and a positive 4.16%.

3D Systems’s highest amplitude of average volatility was 2.44% (last week), 3.31% (last month), and 4.16% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

3D Systems’s EBITDA is 1.81.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.4%, now sitting on 505.95M for the twelve trailing months.

More news about 3D Systems.

10. Plug Power (PLUG) – -7.3%

Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power dropping 7.3% to $4.26 on Wednesday while NASDAQ slid 1.18% to $14,592.21.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.57%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Plug Power’s EBITDA is 3.53.

Volatility

Plug Power’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.67%, a negative 0.05%, and a positive 5.97%.

Plug Power’s highest amplitude of average volatility was 4.67% (last week), 5.08% (last month), and 5.97% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Plug Power’s stock is considered to be overbought (>=80).

More news about Plug Power.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *